ClinicalTrials.gg
CompletedNCT06987513Updated Jul 31, 2026

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

A Phase 2 interventional study of Pemvidutide and Placebo in Alcohol Use Disorder (AUD), sponsored by Altimmune, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Altimmune, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.

Enrollment
390th of 989
100 · median 80
Started
2025
with 55 others
Phase 2
247 of 1,073
38 open now
Registered
1,001st of 1,073
by date

Among the 1,073 studies in Alcoholism with a site in United States, this one is the 390th largest by enrollment of the 989 interventional ones that give a count, is one of 56 that started in 2025, is one of 247 in phase 2, and was the 1,001st registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,073 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms:

  • Pemvidutide: 2.4 mg SC once weekly
  • Placebo: Placebo SC once weekly
03

Conditions studied

  • Alcohol Use Disorder (AUD)

Keywords

  • Pemvidutide
  • GLP-1 receptor agonist
  • Alcohol Use Disorder
  • Obesity
  • Overweight
  • AUD treatment
  • Phase 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written signed prior to performance of any study procedures
  2. Male or female ages 18 to 75 years, inclusive
  3. Diagnosis of current AUD of moderate or greater severity according to criteria
  4. Reported drinking at least 28 drinks per week if male or 21 drinks per week if female in the 28 days prior to signing the informed consent. This should include at least 3 heavy drinking days per week (defined as ≥ 5 drinks per day for men and ≥ 4 drinks per day for women) Note: Baseline heavy drinking days will be determined by the TFLB method (28-day recall) drinking pattern collected at the initial screening visit
  5. Overweight or obesity, defined as ≥ 25 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Presence of alcohol withdrawal symptoms, as defined as CIWA-Ar score ≥ 10 at screening and/or prior to randomization
  2. History of hospitalization for alcohol intoxication or alcohol withdrawal
  3. History of alcohol-related disorders including seizures related to alcohol, MalloryWeiss Syndrome, and alcoholic ketoacidosis
  4. History and/or current diagnosis of schizophrenia, bipolar disorder, psychotic disorder or other severe psychiatric disorders, unless documented as well-controlled by the Investigator and cleared by the Medical Monitor
  5. C-SSRS score indicative of active suicidal thoughts (answering "yes" to any of Questions 2 through 5 on the C-SSRS) in the past 6 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Pemvidutide 2.4 mg

    Drug: Pemvidutide

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Pemvidutide 2.4 mg SC once weekly

  • OtherPlacebo

    Placebo SC once weekly

06

What researchers measure

Primary outcomes

  1. Change from baseline in the average number of heavy drinking days per week

    Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the Timeline Followback (TLFB) method

    Time frame: Baseline to Weeks 21-24

Secondary outcomes

  1. Proportion of subjects achieving a 2-level reduction in WHO risk drinking level

    Proportion of subjects achieving a 2-level reduction in WHO risk drinking level using the TLFB method for the 4-week period comprising Weeks 21 through 24

    Time frame: Baseline to Weeks 21-24

  2. Absolute change from baseline in average phosphatidylethanol (PEth) levels at Week 24

    Time frame: Baseline to Week 24

  3. Change from baseline in average number of drinks per drinking day

    Change from baseline in average number of drinks per drinking day using the TLFB method for the 4-week period comprising Week 21 through 24

    Time frame: Baseline to Weeks 21-24

  4. Change from baseline in proportion of subjects achieving no heavy drinking days

    Change from baseline in proportion of subjects achieving no heavy drinking days using the TLFB method for the 4-week period comprising Week 21 through 24

    Time frame: Baseline to Weeks 21-24

  5. Change from baseline in average percent days completely abstinent

    Change from baseline in average percent days completely abstinent using the TLFB method for the 4-week period comprising Week 21 through 24

    Time frame: Baseline to Weeks 21-24

  6. Change from baseline at Week 24 in average Drinker Inventory of Consequences - Short Inventory of Problems (DrInc-SIP-2R)

    Time frame: Baseline to Week 24

  7. Change from baseline at Week 24 in Patient Reported Outcomes Measurement Information System (PROMIS) Negative Alcohol Consequences (NECO) Short Form

    Time frame: Baseline to Week 24

  8. Percent changes from baseline in body weight

    Time frame: Baseline to Week 24

  9. Percent change from baseline in BMI

    Time frame: Baseline to Week 24

  10. Percent change from baseline in waist circumference

    Time frame: Baseline to Week 24

07

Study locations

12 sites
  • Altimmune Clinical Study Site
    Los Angeles, California 90038, United States
  • Altimmune Clinical Study Site
    Aurora, Colorado 80045, United States
  • Altimmune Clinical Study Site
    New Haven, Connecticut 06511, United States
  • Altimmune Clinical Study Site
    Fort Myers, Florida 33912, United States
  • Altimmune Clinical Study Site
    University Park, Florida 34201, United States
  • Altimmune Clinical Study Site
    North Canton, Ohio 44720, United States
  • Altimmune Clinical Study Site
    Tulsa, Oklahoma 74136, United States
  • Altimmune Clinical Study Site
    Philadelphia, Pennsylvania 19104, United States
  • Altimmune Clinical Study Site
    Providence, Rhode Island 02923, United States
  • Altimmune Clinical Study Site
    Charleston, South Carolina 29425, United States
  • Altimmune Clinical Study Site
    Charlottesville, Virginia 22903, United States
  • Altimmune Clinical Study Site
    Richmond, Virginia 23298, United States
08

References and documents

Individual participant data

Plan to share: Yes — It is anticipated that the results of this study will be presented at scientific meetings and/or published in a peer reviewed scientific or medical journal. A Publications Committee, comprised of the Investigators participating in the study and representatives from the Sponsor, as appropriate, will be formed to oversee the publication of the study results, which will reflect the experience of all participating study centers. Subsequently, individual Investigators may publish results from the study in compliance with their agreement with the Sponsor.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2026, 14 months.

Of 134 phase 2 interventional studies under Alcoholism, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 23, 2025
StartActual
May 15, 2025
Primary completionActual
Jul 30, 2026
CompletionActual
Jul 30, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06987513
Lead sponsor
Altimmune, Inc.
Responsible party
Sponsor
First posted
May 23, 2025
Start date
May 15, 2025
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Jul 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemvidutide

Start the discussion